Form 4 for SLS SELLAS Life Sciences Group, Inc.
Accepted 2026-01-09 00:00:00 ET · period of report 2026-01-07 · accession 0001104659-26-002499 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-01-09 | 2026-01-07 | SLS | Kalin Katherine Bach | Dir | A - Grant | $0.00 | +50.0K | 154.4K | +48% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-01-07 | A | A | 50,000 | $0.00 | 154,400 | D | — | — | (F1) The Reporting Person received an award of 50,000 restricted stock units on January 7, 2026, which shall vest in full on December 1, 2026, subject to the Reporting Person's continued service on the Issuer's Board of Directors through such date. |